on Drägerwerk AG & Co. KGaA (ETR:DRW8)
Drägerwerk Reports Solid Growth in Q1 2026
Drägerwerk AG & Co. KGaA announced robust results for Q1 2026, showing sustained demand across its divisions. Order intake rose to EUR 865 million, up EUR 4 million from the previous year. They recorded net sales of EUR 756 million, marking an increase of approximately EUR 26 million. The company's EBIT surged to EUR 18 million compared to EUR 0.4 million in Q1 2025, reflecting enhanced operational efficiency.
The medical division saw a 5.2% order intake growth, while the safety division posted a slight increase of 1.2%. Both divisions reported net sales growth, with notable improvements in the Americas, EMEA, and Germany.
The company anticipates continuing growth in 2026, projecting a net sales increase of 1.0 to 5.0% and targeting an EBIT margin between 5.0 to 7.5%.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Drägerwerk AG & Co. KGaA news